Compare

Strata Critical Medical/$SRTA

1D1W1M3M6MYTD1Y5YMAX

About Strata Critical Medical

Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.
Ticker
$SRTA
Sector
Health
Primary listing
NASDAQ
Employees
327
Headquarters
New York, United States
Website
www.stratacritical.com

SRTA Metrics

BasicAdvanced
$497M
-
-$0.29
2.56
-

What the Analysts think about SRTA

Analyst ratings (Buy, Hold, Sell) for Strata Critical Medical stock.
Analyst projections of the future price of Strata Critical Medical stock.

Bulls say / Bears say

Clinical is becoming a faster-growing, higher-margin engine: Q3 revenue rose 20.3% sequentially and its gross margin was 25.6%. The larger clinical mix helped lift total gross margin by 110 basis points year on year. (Strata Critical Medical, Inc.)
Cash generation and adjusted profitability improved sharply: Q3 adjusted EBITDA rose to $9.6 million from $4.2 million, its margin reached 13.0%, and free cash flow was $8.6 million. This gives Strata more capacity to fund its plans, including a newly authorised $20 million share buyback. (Strata Critical Medical, Inc.)
The clinical expansion offers scope for further growth through wider coverage and cross-selling. Strata’s three Q2 acquisitions expanded its perfusion and organ-recovery network, while clinical revenue grew 15.1% sequentially excluding those acquisitions and the Statline transition could add up to eight customer relationships. (Strata Critical Medical, Inc.)
GAAP profitability remains elusive: Strata recorded a $7.6 million continuing-operations loss in Q3 and a $3.8 million operating loss. Intangible-asset amortisation alone was $5.5 million. (Strata Critical Medical, Inc.)
The Logistics segment is under pressure: Q3 revenue fell 3.5% year on year and 6.9% sequentially, while gross profit declined 6.6%. Lower transplant volumes and shorter donor-to-recipient distances are weighing on activity and owned-aircraft margins. (Strata Critical Medical, Inc.)
Headline growth depends heavily on acquisitions: although Q3 revenue rose 50.3%, pro forma growth was only 8.5%, and the company attributed the reported increase mainly to acquired clinical businesses. Sustaining rapid growth therefore depends on continued dealmaking and successful integration. (Strata Critical Medical, Inc.)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.

SRTA Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

SRTA Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

SRTA News

AllArticlesVideos

Strata Critical Medical Q3 Earnings Call Highlights

MarketBeat4 days ago

Funds containing SRTA

Funds
Fund name
Fund size
$SRTA weighting
SPDR Russell 2000 US Small Cap€R2US
$5.3B0.01%
SPDR Russell 2000 US Small Cap£R2SC
$5.3B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.